Glucox Biotech (Sweden)
Focus Areas and Applications Pioneering Therapies for Chronic Diseases Glucox Biotech is at the forefront of medical innovation, channeling our expertise into the development of highly selective NOX4 inhibitors. Our dedicated research is centered around creating impactful treatments for diabetic retinopathy, stroke, and kidney disease. This precision-targeted approach is a cornerstone of our expansive drug discovery pipeline, reflecting our commitment to addressing these critical therapeutic are
Basic Information
- Category: business
- Website: http://www.glucoxbiotech.com/
Documented Facts
- Phone: 46709752109 (No linked source recorded for this statement.)
- Email: info@glucoxbiotech.com (No linked source recorded for this statement.)
Evidence and Sources
- Glucox Biotech (Sweden) — Official Site (official)
- Glucox Biotech (Sweden) on linkedin (social)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Glucox Biotech (Sweden).
- Canonical profile: https://brandsource.ai/brands/glucox-biotech-sweden
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/glucox-biotech-sweden/json-ld
- Citation profile API: https://brandsource.ai/api/brands/glucox-biotech-sweden/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (84/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Focus Areas and Applications Pioneering Therapies for Chronic Diseases Glucox Biotech is at the forefront of medical innovation, channeling our expertise into the development of highly selective NOX4 inhibitors. Our dedicated research is centered around creating impactful treatments for diabetic retinopathy, stroke, and kidney disease. This precision-targeted approach is a cornerstone of our expansive drug discovery pipeline, reflecting our commitment to addressing these critical therapeutic are
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 2 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.